Fundamentals data is not available for this company.
| Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-12 | 23.62 | (121.72) | (169.67)¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-13 | 52.79 | (88.46) | (109.75)¢ | n/a | n/a | n/a | n/a | 0.0% |
Copyright © 2012 FactSet Research Systems Inc. All rights reserved.
No recent information was found.
| F.D.A. Rejects Savient’s Gout Drug | 03-Aug-2009 | New York Times |
| Currency | US Dollars |
| Share Price | $ 0.86 |
| Change Today | $ 0.10 |
| % Change | 13.05 % |
| 52 Week High | $8.49 |
| 52 Week Low | $0.75 |
| Volume | 1,265,517 |
| Shares Issued | 72.39m |
| Market Cap | $62.20m |
| Beta | 1.47 |
| RiskGrade | 618 |
| Strong Buy | 2 |
| Buy | 0 |
| Neutral | 5 |
| Sell | 1 |
| Strong Sell | 2 |
| Total | 10 |

| Time | Volume / Share Price |
| 16:00 | 45,283 @ $0.86 |
| 15:59 | 400 @ $0.86 |
| 15:59 | 1,206 @ $0.86 |
| 15:59 | 300 @ $0.86 |
| 15:59 | 600 @ $0.86 |
You are here: research